Figure 3 | Scientific Reports

Figure 3

From: TCR–like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus–transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants

Figure 3

TCR-like mAbs E1, L1 and L2 bind EBV peptide-exchanged HLA-A*02 allelic variants. (A–C) Exchanged complexes of the respective peptides and HLA-A*02 molecules were added onto streptavidin-coated ELISA wells. TCR-like mAbs were 10-fold serially diluted and added into the wells before detection with HRP-conjugated secondary antibodies and readout at OD 415 nm (Supplementary Figure S1). Values were represented as percentage maximum binding and determined by non-linear regression graphs. (D) A*02:01, A*02:03, A*02:06 and A*02:07 EBV BLCLs were acid-stripped and pulsed with EBV EBNA1562-570 (blue), LMP1125-133 (red), LMP2A426-434 (green), Influenza M158-66 (black), in addition to unpulsed control (grey dotted line). Shaded histograms depict the peptides pulsed and their corresponding staining for each TCR-like mAb.

Back to article page